Oncolytics Biotech Inc. ONCY
0.39 USD -0.01 (-2.50%)
At closeNov 3, 2026, 4:21 PM EST
0.38 -0.01 -1.54%
After hours · Nov 3, 4:21 PM ET
0.3816 Day range 0.4072
0.3816 52-week range 1.30
- YTD
- -55.17%
- 1 year
- -64.22%
- Market cap
- 51.14M
- EPS (ttm)
- -0.35
- Shares out
- 77.07M
- Forward P/E
- -3.02
- YTD return
- -55.17%
- 1-year return
- -64.22%
- Volume
- 552.57K
- Avg volume
- 1.04M
- Open
- 0.40
- Previous close
- 0.40
- Day's range
- 0.3816 – 0.4072
- 52-week range
- 0.3816 – 1.30
- Beta
- 1.51
- Price target
- 4.85 (+1144.1%)
1M -0.2159 (-35.98%)
Key statistics
- Enterprise value
- 55.56M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.77M
- Total cash
- 24.85M
- Total debt
- 1.12M
- Return on equity
- -138.22%
- Short % of float
- 3.89%
- 50-day average
- 1.04
- 200-day average
- 1.04
Analyst view
Price target (mean) 4.85
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.1345.
Financials — quick view
ONCY Revenue — quarterly 0
ONCY Net income — quarterly -9.44M
ONCY EPS — quarterly -0.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.08 | -0.09 | -0.01 | -12.50% |
| Aug 1, 2024 | Jun 1, 2024 | -0.08 | -0.07 | +0.01 | +12.50% |
| May 9, 2024 | Mar 1, 2024 | -0.09 | -0.07 | +0.02 | +22.22% |
| Mar 7, 2024 | Dec 1, 2023 | -0.11 | -0.04 | +0.07 | +63.64% |
| Nov 3, 2023 | Sep 1, 2023 | -0.07 | -0.10 | -0.03 | -42.86% |
| Aug 14, 2023 | Jun 1, 2023 | -0.09 | -0.09 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 4, 2024 | Raymond James | init | — | Outperform |
| Mar 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- oncolyticsbiotech.com
News
Oncolytics Biotech Announces Its Group 4 Of Phase 1/2 GOBLET Trial Of Pelareorep In Combination With Atezolizumab Failed to Reach Median Overall Survival 
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers 
Oncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology 
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer 
Oncolytics Biotech Anticipates Reporting Final Results From Group 4 Of Its GOBLET Phase 1/2 Trial In Q4 For Pelareorep With Atezolizumab To Treat Squamous Cell Anal Carcinoma; To Receive Payment Under Grant From Pancreatic Cancer Action Network This Quarter 
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment 
Oncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044 
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update 
Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences 
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Your note
Sign in to keep a note on ONCY — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| International Assets Investment Management, LLC | 0.26% | 198,400 | 179.71K | Jun 29, 2024 |
| Seeds Investor LLC | 0.25% | 189,941 | 172.05K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.11% | 84,998 | 76.99K | Sep 29, 2024 |
| Royal Bank of Canada | 0.10% | 74,546 | 67.52K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.10% | 79,249 | 71.78K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.08% | 61,114 | 55.36K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 41,942 | 37.99K | Oct 30, 2024 |